• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Dr David Cutler Assesses the Political Odds of Drug Pricing Reform

Video

Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.

Legislators from both parties may have difficulty finding a common solution to high drug prices, but President Donald Trump could be instrumental in bringing prices down if he acts on his pledges, according to David M. Cutler, PhD, of Harvard University.

Transcript (slightly modified)

Drug pricing is one area that Democrats and Republicans both agree on. Do you think they might be able to pass legislation addressing rising drug costs? What might it look like?

On drug costs, as with everything in healthcare, the best guess is always no change. I think both Democrats and Republicans are upset that there are people who can’t afford medications, but what they would do about it is very different, and therefore, the ability to compromise is going to be difficult here.

There are things they can do about the FDA, and they’re sort of doing a little bit of that, but the other major issues about things like prices of new medications, price increases, how much you can charge people who are uninsured, things like that, I don’t see a lot of agreement upon.

I think the wild card here is the President, whose sympathies on this seem to lie much more with the Democrats than with the Republicans. So if he decided he really wanted to do something there and he was going to work with the Democrats and bring things along, he really could force the issue more. I don’t know whether he will. So far, he’s governed as a very, very traditional right-wing Republican, and so if that’s the way he’s going to go, the odds that things happen will be very low.

Related Videos
Debra Boyer, MD, MHPE, ATSF.
Mila Felder, MD, FACEP, emergency physician and vice president for Well-Being for All Teammates, Advocate Health
ISPOR 2024 Recap
Screenshot of Stephen Freedland, MD, during a video interview
Phaedra Corso, PhD, associate vice president for research at Indiana University
William Padula, PhD, MSc, MS, assistant professor of pharmaceutical and health economics, University of California Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences
Screenshot of Angela Jia, MD, PhD, during a video interview
Nancy Dreyer, MPH, PhD, FISE, chief scientific advisor to Picnic Health
Screenshot of Alexander Kutikov, MD, during a video interview
Neil Goldfarb, CEO, Greater Philadelphia Business Coalition on Health
Related Content
© 2024 MJH Life Sciences
AJMC®
All rights reserved.